our Premium Content: News alerts, weekly reports and conference planners

GENE:

RICTOR (RPTOR Independent Companion Of MTOR Complex 2)

News alerts, weekly reports and conference planners

22d

Impact of BRAF, TERT, and novel mutations on the efficacy of lenvatinib for advanced papillary thyroid cancer: A national genomic database analysis. (PubMed, NPJ Precis Oncol)

Conclusions Lenvatinib showed substantial efficacy in BRAF-mutated PTC, while TERT mutations did not predict poor outcomes. The identification of five genes associated with early treatment failure highlights the potential for genomic biomarkers to guide personalized therapy.

22 days ago

Journal

BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase) • mTOR (Mechanistic target of rapamycin kinase) • KMT2A (Lysine Methyltransferase 2A) • CREBBP (CREB binding protein) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • MUTYH (MutY homolog)

BRAF mutation • MLL mutation

Lenvima (lenvatinib)

28d

Integrative In Silico mRNA-miRNA Profiling of mTOR Pathway Dysregulation in High-Grade Serous Ovarian Carcinoma. (PubMed, Cancers (Basel))

The mechanistic target of rapamycin (mTOR) pathway is dysregulated in 55% of epithelial ovarian cancers, representing an appealing therapeutic target...In addition, FNIP1, a tumour suppressor gene implicated in mTOR dysregulation, was found to correlate with survival outcomes. We propose a model of dual activation of mTORC1 and autophagy in HGSOC as the metabolic rewiring enabling cancer progression under nutrient and cellular stress.

28 days ago

Journal

RICTOR (RPTOR Independent Companion Of MTOR Complex 2)

sirolimus

Molecular mechanisms and therapeutic targeting implications of ER/mTOR signaling axis-driven tumor progression in aggressive meningiomas. (PubMed, Transl Oncol)

This study revealed that the ER/mTOR axis is associated with sex-linked therapeutic vulnerability in aggressive meningiomas. This finding provides mechanistic evidence for ER-driven mTOR activation via the dysregulation of RICTOR/PIK3CA-DEPTOR. The demonstrated efficacy of tamoxifen supports its clinical repurposing as a targeted therapy for ER-positive meningiomas, offering a biologically rational strategy to address therapeutic resistance in this challenging malignancy.

1 month ago

Journal

ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2)

ER positive

tamoxifen

2ms

Genetic mutations in recurrent and/or metastatic nasal carcinoma: A pathological comparison based on the Japanese national genomic profiling database. (PubMed, Otolaryngol Pol)

These findings underscore the importance of genomic stratification in rare nasal carcinomas. <br><br><b></b> CGP reveals key genetic drivers in nasal carcinoma, supporting its role in precision oncology and informing future subtype-specific therapeutic approaches.

2 months ago

Clinical • Journal • Tumor mutational burden

EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • KMT2D (Lysine Methyltransferase 2D) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2)

FoundationOne® CDx

3ms

Alternative Lengthening of Telomeres in Malignant PEComas: Correlation with Molecular Features Including ATRX Gene Mutation Status. (PubMed, Mod Pathol)

Our study provides the first correlation between ALT and genomic features of malignant PEComas, demonstrating that ATRX alterations invariably predict ALT, but that a subset of tumors without mutations in known ALT suppressor genes also activate ALT. These findings confirm that the association between ATRX alterations and ALT observed in other tumor types applies to PEComas and indicate that in a subset of cases, ALT may be activated by ATRX independent mechanisms.

3 months ago

Journal

ATRX (ATRX Chromatin Remodeler) • TSC1 (TSC complex subunit 1) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3)

3ms

A novel oncogenic nonsense mutation of SMARCA4 and genetic characteristic analysis of SMARCA4 (BRG1)-deficient undifferentiated tumor of the bladder. (PubMed, Virchows Arch)

This suggests that besides SMARCA4 deficiency, alterations in other genes may cooperatively contribute to the tumorigenesis of bladder undifferentiated tumors. These findings provide a reference for subsequent exploration of precise diagnostic and prognostic assessment and treatment strategies for this disease.

3 months ago

Journal • IO biomarker

TP53 (Tumor protein P53) • CCND1 (Cyclin D1) • FGF19 (Fibroblast growth factor 19) • KMT2D (Lysine Methyltransferase 2D) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • KMT2C (Lysine Methyltransferase 2C) • FGF3 (Fibroblast growth factor 3) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • FGF4 (Fibroblast growth factor 4) • GLI1 (GLI Family Zinc Finger 1) • STAG2 (Stromal Antigen 2) • FLT4 (Fms-related tyrosine kinase 4) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • EPHA3 (EPH receptor A3)

3ms

Genomic characterization and prognosis of pancreatic adenosquamous carcinoma. (PubMed, Pancreatology)

Pathway enrichment analysis indicated that STK11 mutations, high tumor mutational burden (TMB-H), APC deletion, TERT/RICTOR amplification, and chromosomal instability (CIN-H) were significantly associated with altered pathways. Additionally, we confirmed the prognostic value of our PASC-specific signature through validation in an independent cohort of pancreatic ductal adenocarcinoma patients.

3 months ago

Journal • Tumor mutational burden

TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TERT (Telomerase Reverse Transcriptase) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2)

TP53 mutation • TMB-H • STK11 mutation • CDKN2A deletion

4ms

SLAP controls mTORC2 integrity via UBE3C-mediated non-degradative mLST8 ubiquitination to suppress colorectal tumorigenesis. (PubMed, Cell Death Differ)

The mechanistic target of rapamycin complex 2 (mTORC2) signaling pathway, which regulates cell growth and migration, exhibits oncogenic function in colorectal cancer (CRC)...In immunodeficient mice CRC xenografts, SLAP depletion enhanced mTORC2 activity and sensitized CRC cells to mTOR catalytic inhibitors. Together, our findings reveal a previously unrecognized SLAP-UBE3C-mLST8 axis that regulates mTORC2 integrity and suggest a potential therapeutic avenue for targeting mTORC2 in CRC.

4 months ago

Journal

RICTOR (RPTOR Independent Companion Of MTOR Complex 2)

sirolimus

4ms

Primary Cutaneous CD30-Positive Lymphoproliferative Disorder With Gamma-Delta T-Cells: A Molecular-Annotated Case With a Classic Clinical Appearance and Behavior. (PubMed, J Cutan Pathol)

Altogether, these findings were insufficient to establish a diagnosis of pcGDTCL. We review the clinical, histopathologic, and molecular sequencing data pertaining to our rare patient as well as the recent literature on indolent CD30+LPD with gamma-delta T-cells.

4 months ago

Journal

HER-2 (Human epidermal growth factor receptor 2) • TNFRSF8 (TNF Receptor Superfamily Member 8) • LRP1B (LDL Receptor Related Protein 1B) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • EPHA7 (EPH Receptor A7)

HER-2 mutation • TNFRSF8 positive

4ms

Case Report: Blood single-cell analysis of a IVB high-grade serous ovarian cancer patient presenting a favorable prognosis. (PubMed, Front Oncol)

This integrative molecular and phenotypic profiling of blood-derived components identified potentially distinct molecular signatures, such as overexpression of IL12, ANGPT1 downregulation and HIF1A downregulation, in the literature described as linked to the patient's beneficial prognosis. These findings suggest that advanced liquid biopsy techniques may provide complementary insights into prognostic biomarkers and therapeutic targets in HGSOC.

4 months ago

Journal

AKT1 (V-akt murine thymoma viral oncogene homolog 1) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • CSF3R (Colony Stimulating Factor 3 Receptor) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • DDIT4 (DNA Damage Inducible Transcript 4) • PGK1 (Phosphoglycerate Kinase 1)

4ms

Bioinformatics Approach to mTOR Signaling Pathway-Associated Genes and Cancer Etiopathogenesis. (PubMed, Genes (Basel))

By distinguishing shared drivers from tumor-specific nodes and elevating non-mutated, topology-inferred candidates, the approach refines biomarker discovery and suggests architecture-aware therapeutic strategies. The analysis is reproducible and extensible, supporting prospective validation of prioritized candidates and the design of correlative studies that align pathway activity with clinical response.

4 months ago

Journal

PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PTEN (Phosphatase and tensin homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • TSC2 (TSC complex subunit 2) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2)

5ms

PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance. (PubMed, Ther Adv Med Oncol)

A genomic expression analysis performed in Cohort #3 (n = 35) showed that a downregulation in the PI3K/AKT/mTOR pathway was mainly evident in the GP group of patients. This integrated multi-step analysis identified potentially altered pathways with a biological impact on squamous-NSCLC oncogenesis, suggesting that the PI3KCA/mTOR pathway could affect the prognosis of resected SCC patients through both genomic aberrations and impaired expression.

5 months ago

Journal

SMAD4 (SMAD family member 4) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • DDR2 (Discoidin domain receptor 2)

PIK3CA mutation